Favorable pregnancy outcome following Trastuzumab (Herceptin) use during pregnancy--Case report and updated literature review.
BACKGROUND
Trastuzumab (Herceptin) is a monoclonal antibody used for the treatment of breast cancer. Experience with use of this agent during pregnancy, and its possible effects on the fetus, is limited.


METHODS
We present a case of a patient with breast cancer who was treated with trastuzumab during the first 24 weeks of pregnancy. This treatment was associated with reversible maternal heart failure, which resolved slowly after the drug was discontinued, but with no adverse fetal effects and a normal infant examination at the age of 2 months. Updated literature review is discussed.
Shrim
Alon
A
The Motherisk Program, Division of Clinical Pharmacology/Toxicology, Hospital for Sick Children, University of Toronto, Ontario, Canada. alon.shrim@gmail.com
Garcia-Bournissen
Facundo
F
Maxwell
Cynthia
C
Farine
Dan
D
Koren
Gideon
G
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002303:Cardiac Output, Low / Q000139:chemically induced; D002585:Cesarean Section; D005260:Female; D005865:Gestational Age; D006801:Humans; D050498:Live Birth; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab